Table 4.
Budget Impact analysis: base case analysis.
| Year 1 | Year 2 | Year 3 | |
|---|---|---|---|
| Reference Scenario | |||
| Anakinra | € 0 | € 0 | € 0 |
| Canakinumab | € 9,808,370 | € 10,195,543 | € 10,582,715 |
| Total | € 9,808,370 | € 10,195,543 | € 10,582,715 |
| Alternative Scenario | |||
| Anakinra | € 311,789 | € 415,719 | € 509,255 |
| Canakinumab | € 5,936,645 | € 5,033,243 | € 4,258,898 |
| Total | € 6,248,434 | € 5,448,961 | € 4,768,153 |
| Δ Alternative – Reference scenario | |||
| Budget Impact: per year | -€ 3,559,936 (−36.3%) |
-€ 4,746,581 (−46.6%) |
-€ 5,814,562 (−54.9%) |
| Budget Impact: cumulative at 3 years | -€ 14,121,080 (−46.2%) |
||
Legend: ADM: Administration; PTS: Patients.
*Costs rounded at the first integer. †Percentages rounded to the first decimal number.